2-Bromoethyl methyl ether → HCID 86637241, compound

HRID 2093414Notes

Reaction equation

HRID 2093414 reaction equation
[Cl:1][C:2]1[N:10]=[C:9]2[C:5]([N:6]=[C:7]([CH2:11][N:12]3[CH2:17][CH2:16][N:15]([S:18]([CH3:21])(=[O:20])=[O:19])[CH2:14][CH2:13]3)[NH:8]2)=[C:4]([N:22]2[CH2:27][CH2:26][O:25][CH2:24][CH2:23]2)[N:3]=1.Br[CH2:29][CH2:30][O:31][CH3:32]>>[Cl:1][C:2]1[N:10]=[C:9]2[C:5]([N:6]=[C:7]([CH2:11][N:12]3[CH2:13][CH2:14][N:15]([S:18]([CH3:21])(=[O:19])=[O:20])[CH2:16][CH2:17]3)[N:8]2[CH2:29][CH2:30][O:31][CH3:32])=[C:4]([N:22]2[CH2:23][CH2:24][O:25][CH2:26][CH2:27]2)[N:3]=1

Participants

3

Reactant 2

HCID 809722-Bromoethyl methyl etherHCID 178504958HCID 178504958, compound

Product 1

HCID 86637241HCID 86637241, compound

Procedure

4-(2-chloro-8-((4-(methylsulfonyl)piperazin-1-yl)methyl)-9H-purin-6-yl)morpholine (215 mg) was reacted with 2-bromoethylmethylether via General Procedure C to give 4-(2-chloro-9-(2-methoxyethyl)-8-((4-(methylsulfonyl)piperazin-1-yl)methyl)-9H-purin-6-yl)morpholine (207 mg) which was reacted with 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole via General Procedure A and purified via reverse phase HPLC to give 21.6 mg 133 as a white solid. MS (Q1) 556.3 (M)+.

Sources & evidence

ORD record
ord-ba1282baf19c44b0aff009bc96bd560b
Source dataset
uspto-grants-2013_05
Patent number
US08445487B2

Reaction notes

Loading…